These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29165816)

  • 1. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
    Pak LM; Kemeny NE; Capanu M; Chou JF; Boucher T; Cercek A; Balachandran VP; Kingham TP; Allen PJ; DeMatteo RP; Jarnagin WR; D'Angelica MI
    J Surg Oncol; 2018 Mar; 117(4):634-643. PubMed ID: 29165816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.
    Adam R; Delvart V; Pascal G; Valeanu A; Castaing D; Azoulay D; Giacchetti S; Paule B; Kunstlinger F; Ghémard O; Levi F; Bismuth H
    Ann Surg; 2004 Oct; 240(4):644-57; discussion 657-8. PubMed ID: 15383792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
    Adam R; Pascal G; Castaing D; Azoulay D; Delvart V; Paule B; Levi F; Bismuth H
    Ann Surg; 2004 Dec; 240(6):1052-61; discussion 1061-4. PubMed ID: 15570210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial.
    Malka D; Verret B; Faron M; Guimbaud R; Caramella C; Edeline J; Galais MP; Bengrine-Lefevre L; Smith D; Dupont-Bierre E; De Baere T; Goéré D; Dartigues P; Lacroix L; Boige V; Gelli M; Pignon JP; Ducreux M
    Eur J Cancer; 2023 Dec; 195():113400. PubMed ID: 37922632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Hepatic Arterial Infusion Pump and Systemic Chemotherapy in the Modern Era for Chemotherapy-Naive Patients with Unresectable Colorectal Liver Metastases.
    Verheij FS; Kuhlmann KFD; Silliman DR; Soares KC; Kingham TP; Balachandran VP; Drebin JA; Wei AC; Jarnagin WR; Cercek A; Kok NFM; Kemeny NE; D'Angelica MI
    Ann Surg Oncol; 2023 Dec; 30(13):7950-7959. PubMed ID: 37639032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery Chemotherapy.
    Datta J; Narayan RR; Goldman DA; Chatila WK; Gonen M; Strong J; Balachandran VP; Drebin JA; Kingham TP; Jarnagin WR; Schultz N; Kemeny NE; D'Angelica MI
    Ann Surg; 2022 Nov; 276(5):e474-e482. PubMed ID: 33214457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Hepatic Artery-Based Therapies and Systemic Multiagent Chemotherapy in Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis.
    Sugumar K; Stitzel H; Wu V; Bajor D; Chakrabarti S; Conces M; Henke L; Lumish M; Mahipal A; Mohamed A; Winter JM; Hardacre JM; Ammori JB; Selfridge JE; Ocuin LM
    Ann Surg Oncol; 2024 Jul; 31(7):4413-4426. PubMed ID: 38502296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer.
    Kemeny NE; Jarnagin WR; Capanu M; Fong Y; Gewirtz AN; Dematteo RP; D'Angelica MI
    J Clin Oncol; 2011 Mar; 29(7):884-9. PubMed ID: 21189384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study.
    Guadagni S; Clementi M; Mackay AR; Ricevuto E; Fiorentini G; Sarti D; Palumbo P; Apostolou P; Papasotiriou I; Masedu F; Valenti M; Giordano AV; Bruera G
    J Cancer Res Clin Oncol; 2020 May; 146(5):1273-1290. PubMed ID: 32088781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A preliminary study of optimal treatment response rates in patients undergoing hepatic arterial infusion chemotherapy combined with molecular targeting and immunotherapy.
    Li M; Liao J; Wang L; Lv T; Sun Q; Xu Y; Guo Z; Quan M; Qin H; Yu H; Zhang K; Xing W; Yu H
    Front Immunol; 2024; 15():1303259. PubMed ID: 38660298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents.
    García-Alfonso P; Ferrer A; Gil S; Dueñas R; Pérez MT; Molina R; Capdevila J; Safont MJ; Castañón C; Cano JM; Lara R
    Target Oncol; 2015 Dec; 10(4):453-65. PubMed ID: 25752908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma.
    Lin ZP; Hu XL; Chen D; Huang DB; Zou XG; Zhong H; Xu SX; Chen Y; Li XQ; Zhang J
    World J Gastroenterol; 2024 May; 30(17):2321-2331. PubMed ID: 38813052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic Artery Infusion Chemotherapy for Primary and Secondary Malignancies of the Liver: State of the Art and Current High-Level Evidence.
    Kuemmerli C; Hess V; Dutkowski P; Sinz S; Kessler U; Hess GF; Billeter AT; Müller-Stich BP; Kollmar O; Müller PC
    Pharmacology; 2024; 109(2):86-97. PubMed ID: 38368862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Factors for the Survival Outcomes of Preoperative Chemotherapy in Patients with Resectable and Borderline Resectable Colorectal Cancer with Liver Metastasis.
    Inworn N; Senavat P; Aleenajitpong N; Chingchaimaneesri M; Siripoon T; Srirattanapong S; Suragul W; Ngamphaiboon N
    Asian Pac J Cancer Prev; 2023 Sep; 24(9):3037-3047. PubMed ID: 37774055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraarterial Chemotherapy for Liver Metastases.
    Connell LC; Kemeny NE
    Surg Oncol Clin N Am; 2021 Jan; 30(1):143-158. PubMed ID: 33220802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Practices in Hepatic Artery Infusion (HAI) Chemotherapy: An International Survey of the HAI Consortium Research Network.
    Judge SJ; Ghalambor T; Cavnar MJ; Lidsky ME; Merkow RP; Cho M; Dominguez-Rosado I; Karanicolas PJ; Mayo SC; Rocha FG; Fields RC; Patel RA; Kennecke HF; Koerkamp BG; Yopp AC; Petrowsky H; Mahalingam D; Kemeny N; D'Angelica M; Gholami S
    Ann Surg Oncol; 2023 Nov; 30(12):7362-7370. PubMed ID: 37702903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic Predictors of Recurrence Patterns After Complete Resection of Colorectal Liver Metastases and Adjuvant Hepatic Artery Infusion Chemotherapy.
    Narayan RR; Datta J; Goldman DA; Aveson VG; Walch HS; Sanchez-Vega F; Gönen M; Balachandran VP; Drebin JA; Jarnagin WR; Kingham TP; Wei AC; Schultz N; Kemeny NE; D'Angelica MI
    Ann Surg Oncol; 2022 Nov; 29(12):7579-7588. PubMed ID: 35896920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis.
    Zacharias AJ; Jayakrishnan TT; Rajeev R; Rilling WS; Thomas JP; George B; Johnston FM; Gamblin TC; Turaga KK
    PLoS One; 2015; 10(10):e0139940. PubMed ID: 26448327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and feasibility of establishing an adjuvant hepatic artery infusion program.
    Janczewski LM; Joung RH; Borhani AA; Lewandowski RJ; Velichko YS; Mulcahy MF; Mahalingam D; Law J; Bowman C; Keswani RN; Poylin VY; Bentrem DJ; Merkow RP
    HPB (Oxford); 2024 May; 26(5):656-663. PubMed ID: 38383208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience.
    Moretto R; Germani MM; Borelli B; Conca V; Rossini D; Boraschi P; Donati F; Urbani L; Lonardi S; Bergamo F; Cerma K; Ramondo G; D'Amico FE; Salvatore L; Valente G; Barbaro B; Giuliante F; Di Maio M; Masi G; Cremolini C
    ESMO Open; 2024 Apr; 9(4):102991. PubMed ID: 38631269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.